Psychiatry Research: Neuroimaging
Volume 162, Issue 2 , Pages 113-121 , 28 February 2008

Metabolic alterations in medication-free patients with bipolar disorder: A 3T CSF-corrected magnetic resonance spectroscopic imaging study

  • John D. Port

      Affiliations

    • Department of Radiology (Mayo E2A), Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 507 538 0348; fax: +1 507 284 1554
    • ,
  • Sencan S. Unal

      Affiliations

    • Department of Psychiatry, Mayo Clinic, Rochester, MN, USA
    • ,
  • David A. Mrazek

      Affiliations

    • Department of Psychiatry, Mayo Clinic, Rochester, MN, USA
    • ,
  • Susan M. Marcus

      Affiliations

    • Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA

Received 28 March 2006 ,Revised 5 July 2007 ,Accepted 6 August 2007.

References 

  1. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience. 1986;9:357–381
  2. Altman EG, Hedeker D, Peterson JL, Davis JM. The Altman self-rating mania scale. Biological Psychiatry. 1997;42:948–955
  3. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: APA; 2000;
  4. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck depression inventories-IA and -II in psychiatric outpatients. Journal of Personality Assessment. 1996;67:588–597
  5. Bertolino A, Frye M, Callicott J, et al. Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging. Biological Psychiatry. 2003;53:906–913
  6. Brambilla P, Harenski K, Nicoletti M, Mallinger A, Frank E, Kupfer D, et al. Anatomical MRI study of basal ganglia in bipolar disorder patients. Psychiatry Research: Neuroimaging. 2001;106:65–80
  7. Brambilla P, Glahn D, Balestrieri M, Soares J. Magnetic resonance findings in bipolar disorder. Psychiatric Clinics of North America. 2005;28:443–467
  8. Castillo M, Kwock L, Courvoisie H, Hooper S, Greenwood R. Proton MR spectroscopy in psychiatric and neurodevelopmental childhood disorders: early experience. Neuroimaging Clinics of North America. 1998;8:901–912
  9. Castillo M, Kwock L, Courvoisie H, Hooper S. Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations. American Journal of Neuroradiology. 2000;21:832–838
  10. Cecil K, DelBello M, Morey R, Strakowski S. Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disorders. 2002;4:357–365
  11. Cecil K, DelBello M, Sellars M, Strakowski S. Proton magnetic resonance spectroscopy of the frontal lobe and cerebellar vermis in children with a mood disorder and a familial risk for bipolar disorders. Journal of Child and Adolescent Psychopharmacology. 2003;13:545–555
  12. Dager S, Friedman S, Parow A, Demopulos C, Stoll A, Lyoo I, et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Archives of General Psychiatry. 2004;61:450–458
  13. Davanzo P, Thomas M, Yue K, Oshiro T, Belin T, Strober M, et al. Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology. 2001;24:359–369
  14. Deicken R, Eliaz Y, Feiwell R, Schuff N. Increased thalamic N-acetylaspartate in male patients with familial bipolar I disorder. Psychiatry Research: Neuroimaging. 2001;106:35–45
  15. Deicken R, Pegues M, Anzalone S, Feiwell R, Soher B. Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder. American Journal of Psychiatry. 2003;160:873–882
  16. De Stefano N, Narayanan S, Francis G, Arnaoutelis R, Tartaglia M, Antel J, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Archives of Neurology. 2001;58:65–70
  17. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders — Patient Edition (SCID-I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996;
  18. Frahm J, Michaelis T, Merboldt K-D, Hanicke W, Gyngell M, Bruhn H. On the N-acetyl methyl resonance in localized 1H NMR spectra of the human brain in vivo. NMR in Biomedicine. 1991;4:201–204
  19. Fukuzako H, Hashiguchi T, Sakamoto Y, Okamura H, Doi W, Takenouchi K, et al. Metabolite changes with age measured by proton magnetic resonance spectroscopy in normal subjects. Psychiatry and Clinical Neurosciences. 1997;51:261–263
  20. Gibbons RD. Mixed-effects models for mental health services research. Health Services and Outcomes Research Methodology. 2000;1:91–129
  21. Guimaraes A, Schwartz P, Prakash M, Carr C, Berger U, Jenkins B, et al. Quantitative in vivo 1H nuclear magnetic resonance spectroscopic imaging of neuronal loss in rat brain. Neuroscience. 1995;69:1095
  22. Hamakawa H, Kato T, Murashita J, Kato N. Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders. European Archives of Psychiatry and Clinical Neuroscience. 1998;248:53–58
  23. Hamakawa H, Kato T, Shioiri T, Inubushi T, Kato N. Quantitative proton magnetic resonance spectroscopy of the bilateral frontal lobes in patients with bipolar disorder. Psychological Medicine. 1999;29:639–644
  24. Harvey NS, Kay R. Compliance during lithium treatment, intra-erythrocyte lithium variability, and relapse. Journal of Clinical Psychopharmacology. 1991;11:362–367
  25. Hedeker D, Gibbons RD. MIXOR: a computer program for mixed-effects ordinal regression analysis. Computer Methods and Programs in Biomedicine. 1996;49:157–176
  26. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology. 1993;43:2689–2695
  27. Kato T, Fujii K, Shioiri T, Inubushi T, Takahashi S. Lithium side effects in relation to brain lithium concentration measured by lithium-7 magnetic resonance spectroscopy. Progress in Neuro-psychopharmacology & Biological Psychiatry. 1996;20:87–97
  28. Kato T, Inubushi T, Kato N. Magnetic resonance spectroscopy in affective disorders. Journal of Neuropsychiatry and Clinical Neurosciences. 1998;10:133–147
  29. McLean MA, Woermann FG, Barker GJ, Duncan JS. Quantitative analysis of short echo time (1)H-MRSI of cerebral gray and white matter. Magnetic Resonance in Medicine. 2000;44:401–411
  30. Meyerhoff DJ, MacKay S, Constans JM, Norman D, Van Dyke C, Fein G, et al. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Annals of Neurology. 1994;36:40–47
  31. Michael N, Erfurth A, Ohrmann P, Gössling M, Arott V, Heindel W, et al. Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology (Berl). 2003;29:639–644
  32. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magnetic Resonance in Medicine. 1994;32:110–115
  33. Moore CM, Breeze JL, Kukes TJ, Rose SL, Dager SR, Cohen BM, et al. Effects of myo-inositol ingestion on human brain myo-inositol levels: a proton magnetic resonance spectroscopic imaging study. Biological Psychiatry. 1999;45:1197–1202
  34. Moore C, Breeze J, Gruber S, Babb S, Frederick B, Villafuerte R, et al. Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex. Bipolar Disorders. 2000;2:207–216
  35. Moore G, Bebchuk J, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds I, et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?. Biological Psychiatry. 2000;48:1–8
  36. Murashita J, Kato T, Shioiri T, Inubushi T, Kato N. Altered brain energy metabolism in lithium-resistant bipolar disorder detected by photic stimulated P-MR spectroscopy. Psychological Medicine. 2000;30:107–115
  37. Murray, C.J.L., Lopez, A.D., Harvard School of Public Health., World Health Organization. and World Bank, 1996. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. [Cambridge, Mass.], Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank: Distributed by Harvard University Press.
  38. Ohara K, Isoda H, Suzuki Y, Takehara Y, Ochiai M, Takeda H, et al. Proton magnetic resonance spectroscopy of the lenticular nuclei in bipolar I affective disorder. Psychiatry Research: Neuroimaging. 1998;84:55–60
  39. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine. 1993;30:672–679
  40. Rajkowska G, Halaris A, Selemon L. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biological Psychiatry. 2001;49:741–752
  41. Sager T, Laursen H, Hansen A. Changes in N-acetyl-aspartate content during focal and global brain ischemia of the rat. Journal of Cerebral Blood Flow and Metobolism. 1995;15:639–646
  42. Sager T, Laursen H, Fink-Jensen A, Topp S, Stensgaard A, Hedehus M, et al. N-Acetylaspartate distribution in rat brain striatum during acute brain ischemia. Journal of Cerebral Blood Flow and Metobolism. 1999;19:164–172
  43. Sassi R, Stanley J, Axelson D, Brambilla P, Nicoletti M, Keshavan M, et al. Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients. American Journal of Psychiatry. 2005;162:2109–2115
  44. Sharma R, Venkatasubramanian P, Barany M, Davis J. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophrenia Research. 1992;8:43–49
  45. Silverstone PH, Asghar SJ, O'Donnell T, Ulrich M, Hanstock CC. Lithium and valproate protect against dextro-amphetamine induced brain choline concentration changes in bipolar disorder patients. World Journal of Biological Psychiatry. 2004;5:38–44
  46. Simmons M, Frondoza C, Coyle J. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience. 1991;45:37–45
  47. Soares JC, Mallinger AG. Intracellular phosphatidylinositol pathway abnormalities in bipolar disorder patients. Psychopharmacology Bulletin. 1997;33:685–691
  48. Strakowski S, DelBello M, Sax K, Zimmerman M, Shear P, Hawkins J, et al. Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. Archives of General Psychiatry. 1999;56:254–260
  49. Strakowski S, DelBello M, Adler C. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Molecular Psychiatry. 2005;10:105–116
  50. Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, Shelton MD, et al. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. Journal of Clinical Psychiatry. 2002;63:1012–1019
  51. Wilke M, Kowatch R, DelBello MP, Mills N, Holland S. Voxel-based morphometry in adolescents with bipolar disorder: first results. Psychiatry Research: Neuroimaging. 2004;131:57–69
  52. Winsberg M, Sachs N, Tate D, Adalsteinsson E, Spielman D, Ketter T. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biological Psychiatry. 2000;47:475–481
  53. Yildiz-Yesiloglu A, Ankerst DP. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2006;30:969–995

☆ Previous presentation: Paper presented at RSNA 90th Scientific Assembly and Annual Meeting, Chicago, IL, November 27–December 3, 2004. (#SSG13-08)

PII: S0925-4927(07)00152-7

doi: 10.1016/j.pscychresns.2007.08.004

Psychiatry Research: Neuroimaging
Volume 162, Issue 2 , Pages 113-121 , 28 February 2008

Article Tools

* Image Usage & Resolution